XML 76 R66.htm IDEA: XBRL DOCUMENT
v3.22.1

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2022 | Mar. 31, 2021
Segment Reporting Information [Line Items] |  |
Sales | $ 15,901 | $ 10,627
Revenue related to the sale of the marketing rights | 114 | 56
U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,339 | 4,790
Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 8,563 | 5,837
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 15,589 | 10,656
Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,246 | 4,731
Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 8,343 | 5,925
Corporate, Non-Segment |  |
Segment Reporting Information [Line Items] |  |
Sales | 312 | (29)
Corporate, Non-Segment | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 93 | 59
Corporate, Non-Segment | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 220 | (88)
Pharmaceutical | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 14,107 | 9,238
Pharmaceutical | Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,773 | 4,294
Pharmaceutical | Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,334 | 4,944
Pharmaceutical | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 4,809 | 3,899
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 2,779 | 2,181
Pharmaceutical | Operating Segments | Keytruda | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 2,030 | 1,718
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |
Segment Reporting Information [Line Items] |  |
Sales | 266 | 228
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 141 | 118
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 125 | 110
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |
Segment Reporting Information [Line Items] |  |
Sales | 227 | 130
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 156 | 85
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 71 | 44
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 27 | 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 25 | 0
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,460 | 917
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 418 | 313
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,042 | 604
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 470 | 449
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 371 | 333
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 99 | 117
Pharmaceutical | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 216 | 158
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 175 | 118
Pharmaceutical | Operating Segments | RotaTeq | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 41 | 41
Pharmaceutical | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 173 | 171
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 118 | 73
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 55 | 99
Pharmaceutical | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 36 | 34
Pharmaceutical | Operating Segments | Vaqta | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 29 | 25
Pharmaceutical | Operating Segments | Vaqta | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 7 | 9
Pharmaceutical | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 395 | 340
Pharmaceutical | Operating Segments | Bridion | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 195 | 167
Pharmaceutical | Operating Segments | Bridion | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 199 | 173
Pharmaceutical | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 94 | 82
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 40 | 35
Pharmaceutical | Operating Segments | Prevymis | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 54 | 47
Pharmaceutical | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 58 | 65
Pharmaceutical | Operating Segments | Primaxin | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 1 | 0
Pharmaceutical | Operating Segments | Primaxin | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 58 | 65
Pharmaceutical | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 57 | 67
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 10 | 15
Pharmaceutical | Operating Segments | Noxafil | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 48 | 52
Pharmaceutical | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 53 | 57
Pharmaceutical | Operating Segments | Cancidas | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 1 | 3
Pharmaceutical | Operating Segments | Cancidas | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 55
Pharmaceutical | Operating Segments | Dificid |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 27
Pharmaceutical | Operating Segments | Dificid | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 49 | 25
Pharmaceutical | Operating Segments | Dificid | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 3 | 2
Pharmaceutical | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 57
Pharmaceutical | Operating Segments | Invanz | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 1 | 4
Pharmaceutical | Operating Segments | Invanz | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 52
Pharmaceutical | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | 30 | (8)
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 18 | (2)
Pharmaceutical | Operating Segments | Zerbaxa | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 12 | (6)
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |
Segment Reporting Information [Line Items] |  |
Sales | 72 | 74
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 71 | 68
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1 | 6
Pharmaceutical | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 55
Pharmaceutical | Operating Segments | Adempas | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 55
Pharmaceutical | Operating Segments | Lagevrio |  |
Segment Reporting Information [Line Items] |  |
Sales | 3,247 | 0
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,523 | 0
Pharmaceutical | Operating Segments | Lagevrio | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,723 | 0
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 158 | 209
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 71
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 97 | 138
Pharmaceutical | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 69 | 79
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 20 | 18
Pharmaceutical | Operating Segments | Belsomra | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 48 | 61
Pharmaceutical | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 186 | 214
Pharmaceutical | Operating Segments | Simponi | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 186 | 214
Pharmaceutical | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 85
Pharmaceutical | Operating Segments | Remicade | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 85
Pharmaceutical | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 779 | 809
Pharmaceutical | Operating Segments | Januvia | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 325 | 348
Pharmaceutical | Operating Segments | Januvia | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 454 | 461
Pharmaceutical | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 454 | 486
Pharmaceutical | Operating Segments | Janumet | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 63 | 84
Pharmaceutical | Operating Segments | Janumet | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 391 | 401
Pharmaceutical | Operating Segments | Other pharmaceutical |  |
Segment Reporting Information [Line Items] |  |
Sales | 520 | 554
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 181 | 212
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 339 | 341
Animal Health | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,482 | 1,418
Animal Health | Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 473 | 437
Animal Health | Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,009 | 981
Animal Health | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 832 | 819
Animal Health | Operating Segments | Livestock | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 171 | 157
Animal Health | Operating Segments | Livestock | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 661 | 662
Animal Health | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 650 | 599
Animal Health | Operating Segments | Companion Animals | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 302 | 280
Animal Health | Operating Segments | Companion Animals | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | $ 348 | $ 319

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |